Dopamine Agonists
Researchers at Purdue University have developed new molecules that fully and selectively activate the dopamine D1 receptor. The compounds derived are useful for treating patients having a dopamine-related dysfunction of the central nervous system (CNS) as well as conditions in which peripheral dopamine receptors are involved. They are expected to be effective against Parkinson's disease, improving cognition, memory, attention deficit hyperactivity disorder, and related developmental disorders.
Lead compound is 50 times more selective for D1 receptors than for D2L receptorsEquipotent, but more selective than other D1 agonists Potentially effective treatment for advanced Parkinson's disease and other CNS disordersOrally bioavailable in animal models
Medical/HealthcarePharmaceuticalsDrug Development
David NicholsPurdue Medicinal Chemistry and Molecular Pharmacology
United States
8,318,938
美國
